Global Burden of Disease 2023 captures a world improving, then aging into a different problem
The newest Global Burden of Disease assessment puts a hard number on a familiar shift in world health: fewer people are dying from many infectious and nutritional causes, while chronic disease, metabolic risk, and mental illness are absorbing a growing share of health loss. Across 204 countries and territories and 660 subnational locations, investigators estimated the burden of 375 diseases and injuries and the attributable burden of 88 modifiable risk factors from 1990 through 2023.
The scale of the exercise matters because it does not measure mortality alone. It measures years lived with disability, years of life lost, and disability-adjusted life-years, which together describe how disease shortens life and erodes function. In 2023, global DALYs reached 2.80 billion, up from 2.64 billion in 2010. Yet age-standardized DALY rates fell 12.6% over the same period. Population growth and aging are expanding the absolute burden even as many age-adjusted risks and outcomes improve.
Noncommunicable disease is now the dominant driver of global disability-adjusted life-years
Noncommunicable diseases accounted for 1.80 billion DALYs in 2023, compared with 1.45 billion in 2010. Their age-standardized rate still slipped 4.1%, which signals an important epidemiologic truth: the world is not simply getting sicker in the same way, but living long enough for chronic disease to dominate the burden profile.
Ischaemic heart disease remained the largest level 3 cause of NCD burden at 193 million DALYs, followed by stroke at 157 million and diabetes at 90.2 million. The burden is moving in two directions at once. Cardiovascular death and disability remain enormous, while diabetes and mental health conditions are rising in age-standardized terms. Anxiety disorders showed the largest increase in age-standardized DALY rates since 2010, up 62.8%, and depressive disorders rose 26.3%. Diabetes also increased, with a 14.9% rise in age-standardized rates.
These trends are biologically coherent. Aging populations accumulate vascular injury, insulin resistance, and neuropsychiatric stressors over decades. As infectious mortality falls, people survive long enough to experience the downstream effects of hypertension, obesity, sedentary behavior, and impaired glucose metabolism. The burden is not merely shifting categories; it is consolidating around long-term exposures that require prevention far earlier than the point of diagnosis.
Communicable disease gains remained substantial despite pandemic disruption
Communicable, maternal, neonatal, and nutritional diseases still accounted for a large share of health loss, but the direction of travel has been favorable. DALYs in this group declined from 874 million in 2010 to 681 million in 2023, while age-standardized rates fell 25.8%. During the COVID-19 pandemic, DALYs from these conditions rose, then returned to pre-pandemic levels by 2023.
The largest rate declines were seen for diarrhoeal diseases, HIV/AIDS, and tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, though both posted notable reductions in age-standardized rates since 2010. The pattern is consistent with better vaccination coverage, improved treatment access, and stronger prevention systems, even if gains were uneven and vulnerable to disruption.
The reversal during the pandemic was brief, but it exposed how quickly fragile gains can be interrupted when routine care, supply chains, and public health services are strained. Infectious disease control has improved, yet those improvements still depend on functioning delivery systems.
Metabolic risk now drives a larger share of the remaining burden
Nearly half of the 2023 global DALY total was attributable to the 88 risk factors analyzed. High systolic blood pressure, particulate matter pollution, high fasting plasma glucose, smoking, and low birthweight with short gestation were the leading contributors. High systolic blood pressure alone accounted for 8.4% of total DALYs.
Metabolic risks stood out as the only broad risk category with rising attributable DALYs between 2010 and 2023, increasing 30.7%, even though age-standardized rates fell 6.7%. High body-mass index, drug use, and high fasting plasma glucose were the three leading level 3 risks whose age-standardized attributable DALY rates rose. High BMI increased 10.5%; drug use rose 8.4%; high fasting plasma glucose rose 6.2%, although that latter change did not reach statistical significance.
The metabolic story is clinically direct. Blood pressure, adiposity, and glycemia are not isolated laboratory values; they are the physiological substrate for stroke, coronary disease, kidney injury, and disability. When those exposures rise across a population, chronic disease follows with a predictable delay. GLP-1 receptor agonists may help at the individual level, but the burden data make clear that drug access alone will not erase the effects of food insecurity, inactivity, air pollution, and structural inequity.
The sharpest gains came from sanitation, infection control, and child health
Many age-standardized risk-attributable DALY rates fell between 2010 and 2023. Unsafe sanitation, unsafe water source, and lack of access to handwashing facilities dropped by more than 45% each. Child growth failure also declined substantially. These are not abstract improvements; they reflect reduced exposure to pathogens, better nutrition, and stronger infrastructure.
The gains carry a warning. They were achieved through long-term investment, and they can be lost if funding contracts. The analysis explicitly points to the risk of major cuts to development assistance for health, with low-income countries facing the largest shock. In settings where infectious disease, undernutrition, and weak health systems still overlap, withdrawal of support would not merely slow progress. It would likely reverse it.
The burden pattern is now a dual crisis of prevention and equity
The 2023 estimates describe two simultaneous realities. First, many of the world’s oldest public health victories have held, even through economic shock and a pandemic. Second, the dominant remaining burdens are increasingly chronic, metabolic, and socially patterned. Cardiovascular disease, diabetes, anxiety, depression, and pollution-related harm are expanding across aging populations, while infectious disease gains remain vulnerable to financing cuts and fragile delivery systems.
The practical implication is not subtle. Prevention must move upstream, toward blood pressure control, smoking reduction, healthier diets, physical activity, vaccination, nutrition support, and cleaner environments. At the same time, health systems have to remain strong enough to preserve the gains already made in infectious and maternal-child health. A narrower focus on treatment alone will miss the larger drivers of disability and premature death.
The most consequential uncertainty is not whether the burden will change again. It will. The question is whether countries will sustain the public health and health-system investments needed to prevent metabolic risk and chronic disease from overwhelming the gains that made the last three decades possible.